Drug and Therapeutics Bulletin 1995;33:17-19; doi:10.1136/dtb.1995.33317
Copyright © 1995 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Methotrexate for rheumatoid arthritis

Relevant BNF section: 10.1.3

Treatment of patients with rheumatoid arthritis (RA) conventionally starts with an analgesic plus a non-steroidal anti-inflammatory drug (NSAID). Slow-acting antirheumatic drugs are being added at an increasingly early stage of the disease.1 When we reviewed slow-acting antirheumatics two years ago1 methotrexate had only recently been licensed in the UK for the treatment of RA. In the USA methotrexate is often preferred to traditional slow-acting antirheumatics such as gold, sulphasalazine and penicillamine. We examine the evidence.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1995 BMJ Publishing Group Ltd.